Vericel reports preliminary 2025 revenue of $276 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vericel Announces Preliminary 2025 Financial Results and Business Updates
January 13, 2026 9:00 AM ESTTotal Revenue Expected to be $276 MillionÂ
MACI Revenue Expected to be $239.5 Million
Fourth Quarter Total Revenue and MACI Revenue Growth of 23%
CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025.
Preliminary, Unaudited Full-Year 2025 Financial Results
Total net... More